medigraphic.com
ISSN 1029-3043 (Electronic)

2012, Number 2

<< Back Next >>

Medicentro 2012; 16 (2)

Treatment of polypoidal choroidal vasculopathy. An update on the diseases

Castillo BG, Chiang RC

Language: Spanish
References: 37
Page: 89-95
PDF size: 74.23 Kb.


ABSTRACT

Macular degeneration related to age, in wet form, is a serious disease that determines legal blindness in many patients. The prognosis in this disease is unfavorable, if not treated. By means of this paper we pretend to present the latest alternatives for treatment of polypoidal choroidal vasculopathy, to achieve this, we conducted a comprehensive review of literature concerning these topics. The results obtained by many authors in regard to the use of different treatments, from the laser photocoagulation to the surgery, were listed. We came to the conclusion that the patient plays a key role in the emergence and subsequent treatment of this disease. Multiple investigations aimed at improving the quality of life of patients with the disease, are being carried out all over the world, and this is still a challenge.


REFERENCES

  1. Boyd S, Lewis H. La colección HIGHLIGHTS- Degeneración macular relacionada con la edad (DMRE) T.2. Panamá: Highlights of Ophthalmology International; 2006.

  2. Yorston D. ¿Qué hay de nuevo en la degeneración macular relacionada a la edad (DMRE)?. Salud Ocular Comunit. 2006;1(2):5-8.

  3. Piñeiro Bustamante A. Retina caso a caso. Barcelona: GLOSA; 2007.

  4. Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP. Polypoidal Choroidal Vasculopathy Masquerading as Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab. Am J Ophthalmol. 2010 Nov.;150(5):666-73.

  5. Klein R, Klein BE, Knudtson M. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmol. 2006;113:373-80.

  6. Bjelakovic G, Nikolova D, Gluud LL. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842-57.

  7. Dimitrios AK, Vasilios S, Artemios K. A case of polypoidal choroidal vasculopathy. Periphery is equally important for such patients. Clin Interv Envejecim. 2009;4:315-7.

  8. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Opthalmol. 2006;142: 660.e1-660.e10.

  9. Barquet LA, Rubio Caso MJ, Puyol Goyta O. Actualización de terapias anti – VEGF en enfermedades de la coroides y la retina. Barcelona: Elsevier; 2010.

  10. The VEGF inhibition study in ocular neovascularization (V.I.S.I.O.N.) clinical trial group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegabtanib for neovascular agerelated macular degeneration. Ophthalmol. 2006;113:1508-21.

  11. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA study group. Ranibizumab for neovascular age – related macular degeneration. N engl J Med. 2006;355:1419-31.

  12. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophtalmol Clin North Am. 2006;19:361-72.

  13. Rosenfeld PJ, Heier JS, Barrer GH, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age – realated macular degeneration. Ophtalmol. 2006;113:632-33.

  14. Heier JS, Antoszyk A, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, et al. Ranibizumab for treatment of neovascular age – related macular degeneration. A phase I/II multicenter, controller, multidose study. Ophtalmol. 2006;113:633-42.

  15. Vedula S, Krzystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2008 Apr. 16;102(2):139-42. Disponible en: http://preview.ncbi.nlm.nih.gov/pubmed/18425911

  16. Rich RM, Rosenfeld PJ, Puliafito CA. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511.

  17. Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92:70-3.

  18. Bashshur ZF, Haddad ZA, Schakal A. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249-56.

  19. Slakter JS, Bochow T, D´Amico DJ. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmol. 2006;113:3-13.

  20. Ito M, Okubo A, Sonada Y, Yamakiri K, Sakamoto T. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration among Japanese patients. Ophthalmol. 2006;220:118-24.

  21. Nicolo M, Ghiglione D, Lai S, Nasciuti F, Cicinelli S, Calabria G. Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina. 2006;26:58-64.

  22. Sacu S, Varga A, Michels S. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study. Br J Ophthalmol. 2008;92:1347-51.

  23. Kondo N, Honda S, Ishibashi K, Tsukahara Y, Negi A. LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population. Am J Ophthalmol. 2007;144(4):608-12.

  24. Cackett P, Wong D, Yeo I. A classification system for polypoidal choroidal vasculopathy. Retina. 2009;29(2):187-91.

  25. Gomi F, Tano Y. Polypoidal choroidal vasculopathy and treatments. Curr Opin Ophthalmol. 2008;19(3):208–12.

  26. Lee MW, Yeo I, Wong D, Ang CL. Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy. Eye. 2009;23(1):145-8.

  27. Tsujikawa A, Ooto S, Yamashiro K, Tamura H, Otani A, Yoshimura N. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol. 2010 Jul.;54(4):310-9.

  28. Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, Ariga H, Kosaka S, et al. Improvement of Angiographic Findings of Polypoidal Choroidal Vasculopathy After Intravitreal Injection of Ranibizumab Monthly for 3 Months. Am J Ophthalmol. 2010 Nov.;150(5):674-82.

  29. Sakurada Y, Kubota T, Imasawa M, Mabuchi F, Tanabe N, Iijima H. ARMS2 Variations in Agerelated Macular Degeneration, Polypoidal Choroidal Vasculopathy, and Retinal Angiomatous Proliferation. Invest Ophthalmol Vis Sci. 2010 Nov.;51(11):5914-9.

  30. Chan WM, Lim TH, Pece A, Silva R, Yoshimura N. Verteporfin PDT for non-standard indications--a review of current literature. Graefes Arch Clin Exp Ophthalmol. 2010;248(5):613- 26.

  31. Mitamura Y, Kitahashi M, Kubota-Taniai M, Yamamoto S. Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: short-term results. Indian J Ophthalmol. 2010;58(4):291-6.

  32. Mori R, Yuzawa M, Lee Z, Haruyama M, Akaza E. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol. 2010;248(9):1233-9.

  33. Jung JH, Lee JK, LeeJE, Oum BS. Result of vitrectomy for breakthrough vitreous hemorrhage associated with age – related macular degeneration and polypoidal choroidal vasculopathy. Retina. 2010;30(6):865-73.

  34. Alós B, Abreu González R, Brandao de Araujo F, Nadal Reus J. Surgical treatment for submacular hemorrhage by pars plana vitrectomy, subretinal rTPA, fluid-air exchange and pneumatic displacement. Arch Soc Canar Oftal. 2008;19:321-6.

  35. Mukai R, Kishi S, Sato T, Watanabe G, Matsumoto H. Protective effect of intravitreal bevacizumab and subtenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapy. Ophthalmologica. 2010;224(5):267-73.

  36. Zuo C, Wen F, Li F, Liu Y, Long S, Huang S, et al. Functional changes following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(2):191-6.

  37. Zuo C, Wen F, Li J, Liu Y, Li M. Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Doc Ophthalmol. 2009;119(1):29-36.




2020     |     www.medigraphic.com